BACKGROUND: Low baroreflex sensitivity (BRS) indicates poor prognosis after acute myocardial infarction. Noninvasive BRS assessment is complicated by nonstationarities and noise in electrocardiogram and pressure signals. Phase-rectified signal averaging is a novel signal processing technology overcoming these problems. OBJECTIVE: To prospectively validate a BRS measure (baroreflex sensitivity assessed by means of phase-rectified signal averaging [BRS(PRSA)]) based on this technology. METHODS: Nine hundred forty-one consecutive acute myocardial infarction survivors aged 80 years or younger in sinus rhythm were prospectively enrolled at 2 German university hospitals. All patients underwent 30-minute recordings of electrocardiogram and arterial blood pressures (Portapres; TNO-TPD Biomedical Instrumentation, Amsterdam, Netherlands) within the first 2 weeks after myocardial infarction. BRS(PRSA) was prospectively dichotomized at 1.58 ms/mm Hg. Primary end point was all-cause mortality at 5 years. Multivariable analyses included Global Registry of Acute Coronary Events score (dichotomized at ≥120), sex, BRS(PRSA), left ventricular ejection fraction (dichotomized at ≤35%), and diabetes mellitus. BRS(PRSA) was compared with 3 standard noninvasive BRS measures, that is, the sequence method, the transfer function method, and the correlation method. RESULTS: During follow-up, 72 patients (7.7%) died. BRS(PRSA) stratified the study population into a high-risk group of 405 patients (≤1.58 ms/mm Hg) with an estimated 5-year mortality of 14.2% and a low-risk group of 536 patients (>1.58 ms/mm Hg) with a 5-year mortality of 2.8% (P <.0001). On multivariable analysis, BRS(PRSA) ≤ 1.58 ms/mm Hg was associated with a hazard ratio of 3.1 (confidence interval 1.7-5.6; P = .001). Predictive power of BRS(PRSA) ≤ 1.58 ms/mm Hg was particularly strong in patients with a Global Registry of Acute Coronary Events score of ≥120 or with a left ventricular ejection fraction of ≤35%. CONCLUSION: BRS(PRSA) is a powerful and independent predictor of mortality in postinfarction patients especially when assessed in patients with a Global Registry of Acute Coronary Events score of ≥120 or a left ventricular ejection fraction of ≤35%.
BACKGROUND: Low baroreflex sensitivity (BRS) indicates poor prognosis after acute myocardial infarction. Noninvasive BRS assessment is complicated by nonstationarities and noise in electrocardiogram and pressure signals. Phase-rectified signal averaging is a novel signal processing technology overcoming these problems. OBJECTIVE: To prospectively validate a BRS measure (baroreflex sensitivity assessed by means of phase-rectified signal averaging [BRS(PRSA)]) based on this technology. METHODS: Nine hundred forty-one consecutive acute myocardial infarction survivors aged 80 years or younger in sinus rhythm were prospectively enrolled at 2 German university hospitals. All patients underwent 30-minute recordings of electrocardiogram and arterial blood pressures (Portapres; TNO-TPD Biomedical Instrumentation, Amsterdam, Netherlands) within the first 2 weeks after myocardial infarction. BRS(PRSA) was prospectively dichotomized at 1.58 ms/mm Hg. Primary end point was all-cause mortality at 5 years. Multivariable analyses included Global Registry of Acute Coronary Events score (dichotomized at ≥120), sex, BRS(PRSA), left ventricular ejection fraction (dichotomized at ≤35%), and diabetes mellitus. BRS(PRSA) was compared with 3 standard noninvasive BRS measures, that is, the sequence method, the transfer function method, and the correlation method. RESULTS: During follow-up, 72 patients (7.7%) died. BRS(PRSA) stratified the study population into a high-risk group of 405 patients (≤1.58 ms/mm Hg) with an estimated 5-year mortality of 14.2% and a low-risk group of 536 patients (>1.58 ms/mm Hg) with a 5-year mortality of 2.8% (P <.0001). On multivariable analysis, BRS(PRSA) ≤ 1.58 ms/mm Hg was associated with a hazard ratio of 3.1 (confidence interval 1.7-5.6; P = .001). Predictive power of BRS(PRSA) ≤ 1.58 ms/mm Hg was particularly strong in patients with a Global Registry of Acute Coronary Events score of ≥120 or with a left ventricular ejection fraction of ≤35%. CONCLUSION: BRS(PRSA) is a powerful and independent predictor of mortality in postinfarction patients especially when assessed in patients with a Global Registry of Acute Coronary Events score of ≥120 or a left ventricular ejection fraction of ≤35%.
Authors: M A Sanchez-Gonzalez; P Guzik; R W May; A P Koutnik; R Hughes; S Muniz; M Kabbaj; F D Fincham Journal: J Hum Hypertens Date: 2014-08-28 Impact factor: 3.012
Authors: Konstantinos D Rizas; Tuomo Nieminen; Petra Barthel; Christine S Zürn; Mika Kähönen; Jari Viik; Terho Lehtimäki; Kjell Nikus; Christian Eick; Tim O Greiner; Hans P Wendel; Peter Seizer; Jürgen Schreieck; Meinrad Gawaz; Georg Schmidt; Axel Bauer Journal: J Clin Invest Date: 2014-03-18 Impact factor: 14.808
Authors: Marta C Antonelli; Martin G Frasch; Mercedes Rumi; Ritika Sharma; Peter Zimmermann; Maria S Molinet; Silvia M Lobmaier Journal: Curr Neuropharmacol Date: 2022 Impact factor: 7.708
Authors: Hein J J Wellens; Peter J Schwartz; Fred W Lindemans; Alfred E Buxton; Jeffrey J Goldberger; Stefan H Hohnloser; Heikki V Huikuri; Stefan Kääb; Maria Teresa La Rovere; Marek Malik; Robert J Myerburg; Maarten L Simoons; Karl Swedberg; Jan Tijssen; Adriaan A Voors; Arthur A Wilde Journal: Eur Heart J Date: 2014-05-05 Impact factor: 29.983
Authors: Daniel Sinnecker; Ralf J Dirschinger; Petra Barthel; Alexander Müller; Adrian Morley-Davies; Alexander Hapfelmeier; Michael Dommasch; Katharina M Huster; Gerd Hasenfuss; Karl-Ludwig Laugwitz; Marek Malik; Georg Schmidt Journal: J Am Heart Assoc Date: 2014-06-03 Impact factor: 5.501